2026-05-22T00:33:31Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/225662024-11-29T05:41:02Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Rubiño Díaz, Jose Ángel author Andres, Pilar author 2018-08-14 One current challenge for neuropsychologists is to design assessment methods capable of detecting cognitive deficits in the early or preclinical phases of Alzheimer's disease (AD). The objective of this paper is to review the studies that have explored the use of the Face-Name Associative Memory Exam (FNAME) as a test for early diagnosis of AD. Studies looking at correlations between performance on the FNAME test and biomarkers in healthy people and studies comparing healthy controls and people with mild cognitive impairment are reviewed. These studies are based on the evidence that AD's pathological process begins years before the most visible clinical manifestations. We conclude that the FNAME test may be a valuable tool for early diagnosis but that some important questions remain to be resolved in future research. Rubino J, Andres P. The Face-Name Associative Memory Test as a Tool for Early Diagnosis of Alzheimer's Disease. Front Psychol. 2018 Aug 14;9:1464. 10.3389/fpsyg.2018.01464 1664-1078 Frontiers in Psychology http://hdl.handle.net/20.500.13003/9172 30154753 2-s2.0-85051476777 https://hdl.handle.net/20.500.12105/22566 441700600001 Alzheimer's disease Early diagnosis Mild cognitive impairment Neuropsychological evaluation FNAME Associative memory The Face-Name Associative Memory Test as a Tool for Early Diagnosis of Alzheimer's Disease